{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-079684","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.887367+00:00","generated_at":"2026-06-13T10:32:10.271030+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Iovance reports ~$317M cash as of June 30; authorized shares increased to 500M","bullets":["Preliminary cash, equivalents, short-term investments, and restricted cash ~$317M as of June 30, 2023 (unaudited).","Stockholders approved increase in authorized common stock from 300M to 500M at June 6 annual meeting; certificate filed June 9.","The cash estimate is subject to change upon completion of quarter-end closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-079684","json":"https://secwatch.observer/filing/0001104659-23-079684.json","markdown":"https://secwatch.observer/filing/0001104659-23-079684.md","text":"https://secwatch.observer/filing/0001104659-23-079684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/0001104659-23-079684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/tm2320915d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:32:10.271030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}